Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 1:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 689 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Sodium chloride injection (0.9%) Clear all
Completed Phase 3 Interventional Results available

A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1

NCT03681184
View directory record Official record
Conditions
Primary Hyperoxaluria Type 1 (PH1)
Interventions
Placebo, Lumasiran
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
6 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
5
States / cities
San Diego, California • Jacksonville, Florida • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Oct 9, 2026, 1:02 AM EDT
Terminated Phase 3 Interventional Results available

Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer

NCT02049151
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Tecemotide, Placebo, Cyclophosphamide (CPA), Saline (sodium chloride)
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 23, 2017 · Synced Oct 9, 2026, 1:02 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

A Prospective Randomized Double Blinded Controlled Trial of Non-Operative Management of TFCC Injuries

NCT03830775
View directory record Official record
Conditions
Wrist Injuries, PRP
Interventions
Platelet-rich plasma (PRP)
Procedure
Lead sponsor
Edna Rath
Federal
Eligibility
Not listed
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 9, 2026, 1:02 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive Disorder

NCT01482221
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
AZD6765 iv, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
542 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
33
States / cities
Chino, California • Lond Beach, California • San Diego, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 9, 2026, 1:02 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years

NCT05468736
View directory record Official record
Conditions
COVID-19
Interventions
SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), Placebo
Biological · Other
Lead sponsor
Novavax
Industry
Eligibility
6 Months to 11 Years
Enrollment
3,600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
47
States / cities
Little Rock, Arkansas • Anaheim, California • Bellflower, California + 41 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 9, 2026, 1:02 AM EDT
Terminated Phase 2 Interventional

Phase 2B Micronized DHACM vs. Saline in the Treatment of Knee Osteoarthritis

NCT05796765
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Micronized DHACM 40 mg, Micronized DHACM 100 mg, Saline
Biological · Drug
Lead sponsor
MiMedx Group, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
14
States / cities
La Mesa, California • Miami, Florida • The Villages, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Oct 9, 2026, 1:02 AM EDT
Terminated Phase 2 Interventional Results available

Trial of NanoPac Focal Therapy for Prostate Cancer

NCT04221828
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma, Prostate Cancer Adenocarcinoma, Prostatic Neoplasm, Urogenital Neoplasms, Genital Neoplasms, Male, Localized Cancer
Interventions
NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension
Drug
Lead sponsor
NanOlogy, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
4
States / cities
Tampa, Florida • Kansas City, Kansas • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2022 · Synced Oct 9, 2026, 1:02 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies

NCT00481871
View directory record Official record
Conditions
Relapsed or Refractory Lymphoproliferative Malignancies, Hodgkin's Lymphoma, Peripheral T-cell Lymphoma, B-cell Lymphoma, Waldenstrom's Macroglobulinemia
Interventions
Pralatrexate Injection, Gemcitabine Hydrochloride, Vitamin B12, Folic Acid
Drug · Dietary Supplement
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
15
States / cities
Los Angeles, California • Stanford, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2020 · Synced Oct 9, 2026, 1:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluate the Safety, Tolerability and PK of HF1K16 in Healthy Volunteers

NCT05386823
View directory record Official record
Conditions
Healthy
Interventions
HF1K16, Placebo
Drug
Lead sponsor
HighField Biopharmaceuticals Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Oct 9, 2026, 1:02 AM EDT
Not listed Phase 2 Interventional

Use of Monoclonal Antibodies for the Treatment of Mild to Moderate COVID-19 in Non-Hospitalized Setting

NCT04840459
View directory record Official record
Conditions
Covid19
Interventions
BAMLANIVIMAB, CASIRIVIMAB, IMDEVIMAB
Biological
Lead sponsor
Sohail Rao
Other
Eligibility
12 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Edinburg, Texas • Rio Grande City, Texas
Source: ClinicalTrials.gov public record
Updated Mar 29, 2022 · Synced Oct 9, 2026, 1:02 AM EDT
Completed Phase 2 Interventional Results available

A Study of LY2189102 in Patients With Type 2 Diabetes

NCT00942188
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
LY2189102, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
20 Years to 75 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
18
States / cities
Mobile, Alabama • Anaheim, California • Chula Vista, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced Oct 9, 2026, 1:02 AM EDT
Completed Phase 2 Interventional Results available

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

NCT00787761
View directory record Official record
Conditions
Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic HSCT
Biological · Drug · Procedure
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
Up to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 1, 2012 · Synced Oct 9, 2026, 1:02 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Anthrax AV7909 Boost Evaluation Study

NCT05997264
View directory record Official record
Conditions
Anthrax
Interventions
AV7909 Full Dose (0.5 mL), AV7909 Half Dose (0.25 mL), Placebo: Sodium Chloride Injection, USP 0.9% (0.5 mL), Placebo: Sodium Chloride Injection, USP 0.9% (0.25 mL)
Biological
Lead sponsor
Biomedical Advanced Research and Development Authority
Federal
Eligibility
18 Years to 65 Years
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
7
States / cities
Hickory, North Carolina • Salisbury, North Carolina • Statesville, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 9, 2026, 1:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety and Immunogenicity Study of Heterologous and Homologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

NCT02325050
View directory record Official record
Conditions
Healthy
Interventions
MVA-BN-Filo, Ad26. ZEBOV, Placebo
Biological · Other
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 50 Years
Enrollment
164 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 9, 2026, 1:02 AM EDT
Terminated Phase 1 Interventional

Trial of OnabotulinumtoxinA for Depression in Parkinson Disease

NCT03069911
View directory record Official record
Conditions
Parkinson Disease, Depression
Interventions
OnabotulinumtoxinA, Control
Biological
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 95 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Oct 9, 2026, 1:02 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)

NCT04199689
View directory record Official record
Conditions
Papillomavirus Infections
Interventions
9vHPV Vaccine, Placebo (Saline for Injection)
Biological · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
20 Years to 45 Years · Male only
Enrollment
6,033 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
32
States / cities
Northridge, California • Rialto, California • Simi Valley, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 9, 2026, 1:02 AM EDT
Withdrawn Phase 2 Interventional

Incobotulinum Toxin A for Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS)

NCT01565395
View directory record Official record
Conditions
Parkinson Disease, Amyotrophic Lateral Sclerosis
Interventions
Incobotulinum Toxin A, placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
20 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Oct 9, 2026, 1:02 AM EDT
Not listed Phase 2Phase 3 Interventional Accepts healthy volunteers

Immuno-bridging and Broadening Study of a Whole, Inactivated COVID-19 Vaccine BBV152 in Healthy Adults

NCT05258669
View directory record Official record
Conditions
COVID-19
Interventions
BBV152
Biological
Lead sponsor
Ocugen
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
10
States / cities
Tempe, Arizona • Miami, Florida • Miami Lakes, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Oct 9, 2026, 1:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects.

NCT02963909
View directory record Official record
Conditions
Zika Virus Infection
Interventions
IXIARO, Placebo, YF Vax 17D Strain, Zika Virus Purified Inactivated Vaccine (ZPIV)
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Oct 9, 2026, 1:02 AM EDT
Completed Phase 4 Interventional Results available

Trial Liposomal Bupivacaine Following Retropubic Suburethral Sling for Stress Urinary Incontinence

NCT02296099
View directory record Official record
Conditions
Urinary Incontinence, Stress
Interventions
liposomal bupivacaine, Placebo
Drug
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years and older · Female only
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Oct 9, 2026, 1:02 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Extended Release Local Anesthetic for Postsurgical Pain After Posterior Colporrhaphy and Perineorrhaphy

NCT03875664
View directory record Official record
Conditions
Postoperative Pain
Interventions
Liposomal bupivacaine, Placebo - injection
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Oct 9, 2026, 1:02 AM EDT
Terminated Phase 2 Interventional Results available

Phase IIb Study of IFN-K in Systemic Lupus Erythematosus

NCT02665364
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
IFNα-Kinoid, Placebo, ISA 51 VG
Biological · Other
Lead sponsor
Neovacs
Industry
Eligibility
18 Years to 65 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
13
States / cities
Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2020 · Synced Oct 9, 2026, 1:02 AM EDT
Completed Not applicable Interventional Results available

Safety and Effectiveness of Monovisc® Injection for Osteoarthritis of the Knee

NCT00653432
View directory record Official record
Conditions
Osteoarthritis
Interventions
Monovisc®, Saline
Device · Other
Lead sponsor
Anika Therapeutics, Inc.
Industry
Eligibility
35 Years to 75 Years
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
30
States / cities
Hoover, Alabama • Mesa, Arizona • Phoenix, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Oct 9, 2026, 1:02 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis.

NCT00314132
View directory record Official record
Conditions
Encephalitis, Japanese Encephalitis
Interventions
ChimeriVax-JE, Japanese Encephalitis vaccine, 0.9% Saline
Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
2,004 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
16
States / cities
Burbank, California • Costa Mesa, California • Davis, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2012 · Synced Oct 9, 2026, 1:02 AM EDT